Search Results
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
Bosaya™ 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso™ 120 mg/1.7 mL (70 mg/mL injection for subcutaneous use in a single-dose vial, are biosimilars to Amgen's Prolia® and Xgeva®, respectively.
More news about: Biocon Biologics
Oct 01, 2025, 07:00 ET Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
maintaining syringeability, which is the ability to inject smoothly and easily. Hypercon™ enables biologic product formulation concentrations of 400-500 mg/ml, which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today. The increased concentration reduces the volume
More news about: Halozyme Therapeutics, Inc.
Oct 01, 2025, 01:00 ET JarnisTech Offers PCB Design and Assembly Services to Startups and R&D Teams
www.jarnistech.com Photo - https://mma.prnewswire.com/media/2785616/MG_9356.jpg
More news about: JarnisTech
Sep 30, 2025, 18:28 ET Efeito semaglutida: estudo inédito da WGSN revela como inovação no tratamento da obesidade está redesenhando o futuro dos mercados e da sociedade
cardiovascular. O compromisso com a evolução é contínuo, e o estudo STEP-UP, por exemplo, já demonstrou que uma dose mais alta de Wegovy® (semaglutida 7,2 mg) pode levar a uma perda de peso de 21%, com um terço dos participantes perdendo 25% ou mais de seu peso basal, estabelecendo um novo patamar de eficácia",
More news about: Novo Nordisk
Sep 30, 2025, 09:00 ET FDA dos EUA aprova Inluriyo (imlunestrant) para adultos com câncer de mama avançado ou metastático ER+, HER2- e com mutação ESR1
fator de crescimento epidérmico humano (HER2–). Inluriyo é um medicamento oral aprovado pela FDA dos EUA, em comprimidos de 200 mg, administrado em dose única diária de 400 mg, tomado com o estômago vazio, pelo menos 2 horas antes ou 1 hora após a alimentação. Inluriyo também está sendo estudado em combinação
More news about: Eli Lilly do Brasil
Sep 30, 2025, 08:48 ET Combining Calcium and Vitamin C to Manage Mild Osteoporosis
1,000 and 1,200 mg of calcium daily. This can come from sources like yogurt, milk, and cheese. It can also come from certain leafy green vegetables, like broccoli,
More news about: Synevit
Sep 30, 2025, 08:31 ET PLT Wants People to 'Feel the Science' at SupplySide Global 2025, Showcasing New Science, New Ingredients and New Ideas
improvement in completing complex tasks and enhanced mood – often in as little as 30 minutes. In a second clinical study, a 40 mg dose of Dynagenix was demonstrated to promote joint comfort and post-exercise muscle recovery, offering the ability to function at a higher level in
More news about: PLT Health Solutions
Sep 30, 2025, 08:00 ET Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout
tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors (XOIs) and last-line uricase therapy. Currently, no suitable second-line
More news about: Crystalys Therapeutics
Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI.
More news about: Acurx Pharmaceuticals, Inc.
Sep 29, 2025, 15:08 ET More Ways to Sip Healthy: Javvy Coffee Expands Its Sprouts Selection with Collagen Creamer and Concentrates
coffee drinks, hot or cold, without the hassle. Simply add 1–2 teaspoons to water or milk, and you're ready to enjoy a premium coffee experience with 80mg of caffeine. Made with 100% real coffee, no sugar, no chemicals, and better-for-you ingredients, it's a convenient, better-for-you
More news about: Javvy Coffee
Sep 29, 2025, 14:17 ET Fusion CBD Products' Wiggles and Paws Could Help Dogs, Cats, and Horses
that investigated the usefulness of treating dogs with CBD to alleviate the stress of car travel. It found that treating dogs once a day orally with 4 mg/kg of CBD led to decreased cortisol levels, less whining, and less lip licking – all signs of stress in dogs. Dogs treated with the same amount of CBD
More news about: Fusion CBD Products
Sep 29, 2025, 08:00 ET PureHealth Research Launches New Ashwagandha Supplement to Combat Modern Stress
Ashwagandha supplement features a premium-grade, whole-root Ashwagandha extract in a potent 600mg daily serving . It is carefully formulated to deliver a range of tangible health benefits:
More news about: PureHealth Research
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion. ABOUT JOHNSON & JOHNSONAt
More news about: Johnson & Johnson
Sep 29, 2025, 07:00 ET Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations.
patients with primary humoral immunodeficiency (NCT03961009). A total of 47 patients received intravenous infusion of QIVIGY at the dose of 266 to 826 mg/kg every 3 or 4 weeks for 12 months. Thirty-nine and 8 patients were administered QIVIGY on a 4-week or a 3-week infusion cycle, respectively.
More news about: Kedrion Biopharma
Sep 29, 2025, 06:00 ET AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
Strong safety and tolerability: ROC-101 was safe and well-tolerated at all doses tested, up to 40 mg once daily. The study found no evidence of hypotension at any dose.Among those receiving ROC-101, the most common treatment emergent
More news about: AllRock Bio
Sep 29, 2025, 02:38 ET Leqembi® approved for IV maintenance treatment in China
as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued. AD
More news about: BioArctic
Sep 29, 2025, 02:34 ET Leqembi® approved for IV maintenance treatment in China
as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued. AD
More news about: BioArctic
Sep 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Pomerantz LLP
Sep 26, 2025, 11:42 ET Desert Harvest Launches 1st Human-Identical Lactoferrin for Menopause
in menopause and beyond. Targeted Menopause Support with Clinically Proven Aloe The new Desert Harvest supplement combines 300 mg of effera™ with its proprietary Super Strength Aloe Vera, used for decades to soothe mucosal tissue and aid nutrient absorption.
More news about: Desert Harvest
Sep 26, 2025, 08:45 ET AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
randomized, placebo-controlled, parallel-group, 27-week trial to evaluate the efficacy, safety and tolerability of flexible doses of tavapadon (5-15 mg QD) in early Parkinson's disease. The primary endpoint was the change from baseline in the MDS-UPDRS Parts II and III combined score. Key secondary endpoints
More news about: AbbVie
Sep 26, 2025, 08:00 ET New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 Neuromuscular Study Group Annual Scientific Meeting
Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment. Gastrointestinal Disturbances:
More news about: ITF Therapeutics LLC
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of FILSPARI (sparsentan), compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving at least 50% of max
More news about: Vifor International AG (CSL Vifor)
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of FILSPARI (sparsentan), compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving at least 50% of max
More news about: Vifor International AG (CSL Vifor)
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
epidermal growth factor receptor 2-negative (HER2–) breast cancer. Inluriyo is a U.S. FDA approved oral prescription medicine, 200 mg tablets taken as a once-daily dose of 400 mg taken on an empty stomach, at least 2 hours before food or 1 hour after food. Inluriyo is also currently being studied in combination
More news about: Eli Lilly and Company
Sep 25, 2025, 12:00 ET REIGN Total Body Fuel™ Unveils Newest Ambassador DeMarcus Lawrence
defensive line mirror the ethos in every can of REIGN TBF. We're thrilled to have him join our lineup of elite ambassadors." Formulated with 300mg of natural caffeine, zero sugar, branched-chain amino acids (BCAAs), CoQ10, and electrolytes, REIGN TBF is engineered for those who demand more of themselves
More news about: REIGN Total Body Fuel